UTILISATIONS D'INHIBITEURS DE PD-1/PD-L1 ET/OU D'INHIBITEURS DE CTLA-4 AVEC UN AGENT BIOLOGIQUE CONTENANT DE MULTIPLES COMPOSANTS DE CYTOKINE POUR TRAITER LE CANCER
HADDEN, JOHN W.,BERINSTEIN, NEIL L.,EGAN, JAMES E.
申请号：
CA3034266
公开号：
CA3034266A1
申请日:
2017.08.18
申请国别(地区):
CA
年份:
2018
代理人:
摘要：
Aspects of the disclosure relate to methods for treating cancer, e.g., by administering to a subject having cancer a primary cell-derived biologic with multiple cytokine components in combination with an antagonist of programmed cell death-ligand 1 (PD-L1) or programmed cell death 1 (PD-1) and/or with an antagonist of cytotoxic T-lymphocyte- associated protein 4 (CTLA-4). Other aspects of the disclosure relate to methods of identifying a subject for treatment with an antagonist of PD-L1 or PD-1 and/or an antagonist of CTLA-4 or assessing the likelihood that a subject will be responsive to an antagonist of PD-L1 or PD-1 and/or an antagonist of CTLA-4.
